Characteristics of melatonin-forming disorders of the epiphysis in hemodialysis patients depending on clinical and demographic parameters

V.  Kondratiuk; A.  Petrova

doi:10.31450/ukrjnd.1(65).2020.06

V. Kondratiuk Bogomolets National Medical University https://orcid.org/0000-0002-4891-2338
A. Petrova Bogomolets National Medical University

DOI: https://doi.org/10.31450/ukrjnd.1(65).2020.06

Keywords: melatonin, melatonin-forming function, chronic kidney disease, hemodialysis.

Abstract

Current scientific studies’ results have shown the relationship between the epiphysis functional state and the kidneys function. However, the impaired of the epiphysis melatonin-forming function (MFE) in patients with chronic kidney disease (CKD) undergoing hemodialysis (HD) is a poorly understood issue.

Methods. 130 HD patients (50% of men) were examined in this study. Based on the melatonin level, the patients were allocated into 2 groups: group I included 110 HD patients with impaired MFE and group II consisted of 20 HD patients with preserved MFE. 20 healthy individuals were included in the control group.

Results. The melatonin level was significantly lower in HD patients compared to the control group at daytime and night (p <0.001). MFE disorder were diagnosed in 84.6% HD patients. The group I patients had significantly higher BMI (p = 0.01), waist volume (p = 0.04), duration of HD treatment (p = 0.01) and arterial pressure (p <0.001) compared with the second group. Moreover, the increased level of C-reactive protein (p <0.001), total cholesterol (p < 0.05), triglycerides (p <0.05) and a lower serum albumin level (p <0.01) were observed in the patients of group I compared with the second one. The melatonin levels at daytime and night were significantly correlated with the patients’ age (r = -0.42; p <0.001 and r = -0.40; p <0.001), HD treatment duration (r = -0.64; p <0.001 and r = -0.65; p <0.001), BMI (r = -0.22; p = 0.006 and r = -0.33; p <0.001) and arterial pressure (r = -0.66; p <0.001 and r = -0.84; p <0.001). In addition, albumin, hemoglobin and serum uric acid concentration were associated with the melatonin level.

Conclusions. The violation of MFE was diagnosed in 84.6% of HD patients and determined by the duration of the dialysis treatment, the blood pressure, body weight, hemoglobin level, the degree of impaired protein and purine metabolism.

Downloads

Download data is not yet available.

References

Dudar I.O., Palamar B.I., Krasiuk E.K., Petrova A.S. Poshyrenist KhKhN VD stadii u sviti ta v Ukraini. Zdorovia Ukrainy. 2015; 3–4: 10-12 [In Ukrainian].

Smirnov A.V. Zamestitel'naja pochechnaja terapija. Nefrologija. 2011; 1: 33-46. [In Russian].

Byjean A. Boutin. How Can Molecular Pharmacology Help Understand the Multiple Actions of Melatonin: 20 Years of Research and Trends. November 21st 2018: 13-21. doi: 10.5772/intechopen.79524. Amaral FGD, Andrade-Silva J, Kuwabara WMT, Cipolla-Neto J. New insights into the function of melatonin and its role in metabolic disturbances. Expert Rev Endocrinol Metab. 2019; 14(4):293-300. doi: 10.1080/17446651.2019.1631158.

Jihwan Myung, Mei-Yi Wu, Chun-Ya Lee, Amalia Ridla Rahim,Vuong Hung Truong, Dean Wu, et al. Contributes to Timekeeping by the Master Circadian Clock. Int J Mol Sci. 2019; 20(11): 2765. doi: 10.3390/ijms20112765.

Takeuchi S, Nawashiro H. Circadian rhythms of serum atrial natriuretic peptide. Acta Neurochir. 2011;153(5):1153. doi: 10.1007/s00701-011-0951-3.

Vasil'eva I. A., Petrova N. N. Sovremennye podhody k psihologicheskoj reabilitacii bol'nyh s hronicheskoj pochechnoj nedostatochnost'ju: Posobie dlja vrachej. – SPb., 2010; 92-94 [In Russian].

Ishigaki S, Ohashi N, Matsuyama T. Melatonin ameliorates intrarenal renin–angiotensin system in a 5/6 nephrectomy rat model. Clinical and Experimental Nephrology. 2017; 22(3): 539-549. doi: 10.1007/s10157-017-1505-7.

Peng W., Lei M., Zhang J., Zhang Y. The protective effect of melatonin on the in vitro development of yak embryos against hydrogen peroxide-induced oxidative injury. Cambridge University Press. 2019; 27(3): 118-125. doi: https://doi.org/10.1017/S0967199418000412.

Bulyk R. E. Uchastie peptidov shishkovidnoj zhelezy v obespechenii funkcij fotoperiodicheskoj sistemy golovnogo mozga i pochek (obzor literatury i sobstvennye issledovanija). Bukovins'kij medichnij vicnik. 2012; 16(3):67-71 [In Russian].

Jos Cipolla-Neto, Fernanda Gaspar do Amaral. Melatonin as a Hormone: new physiological and clinical insights. Endocrine Reviews. 2018; 39(6): 990–1028. doi: 10.1210/er.2018-00084.

Kaladze NN., Slobodjan EI., Govdaljuk AL. Jepifizarnyj gormon melatonin i hronicheskaja bolezn' pochek (obzor literatury i sobstvennye issledovanija). Zhurnal Zdorov'e rebenka. 2015; 2 (61): 183-188. [In Russian].

Amaral FGD, Andrade-Silva J, Kuwabara WMT, Cipolla-Neto J. New insights into the function of melatonin and its role in metabolic disturbances. Expert Rev Endocrinol Metab. 2019; 14(4):293-300. doi: 10.1080/17446651.2019.1631158.

Koch B.C.P., van der Putten K., Van Someren J. W. et al. Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (CREAM study). Nephrol. Dial. Transplant. 2010; 25(2):513–519. doi: 10.1093/ndt/gfp493.

Maung SC, El Sara A, Chapman C, Cohen D, Cukor D. Sleep disorders and chronic kidney disease. World J Nephrol 2016; 5(3): 224-232. doi: https://dx.doi.org/10.5527/wjn.v5.i3.224.

Russcher M, Nagtegaal JE, Nurmohamed SA, Koch BC, van der Westerlaken MM, van Someren EJ, et al. The effects of kidney transplantation on sleep, melatonin, circadian rhythm and quality of life in kidney transplant recipients and living donors. Nephron 2015;129: 6-15. doi: 10.1159/000369308.

Hrenak J, Paulis L, Repova K, Aziriova S, Nagtegaal EJ, Reiter RJ et al. Melatonin and renal protection: novel perspectives from animal experiments and human studies (review). Curr Pharm Des. 2015; 21(7):936-49. doi: 10.2174/1381612820666140929092929.

Reiter RJ, Tan DX, Paredes SD, Fuentes-Broto L. Benefi cial effects of melatonin in cardiovascular disease. Annals of medicine. 2010; 42(4): 276–285. doi: 10.3109/07853890903485748.

Loloei S, Sepidarkish M, Heydarian A, Tahvilian N, Khazdouz M, Heshmati J, et al. The effect of melatonin supplementation on lipid profile and anthropometric indices: A systematic review and meta-analysis of clinical trials. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019; 13(3):1901-1910. doi: 10.1016/j.dsx.2019.04.043.

Mohammadi-Sartang М., Ghorbani М., Mazloom Z. Meta-analyses: Effects of melatonin supplementation on blood lipid concentrations: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition. 2018:37:1943-1954. doi: https://doi.org/10.1016/j.clnu.2017.11.003.

Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018; 175(16): 3190-3199. doi: 10.1111/bph.14116.

Jermaine G.Johnston, David M.Pollock. Circadian regulation of renal function. Free Radical Biology and Medicine. 2018; 119: 93-107. doi: 10.1016/j.freeradbiomed.2018.01.018.

Maarman GJ, Andrew BM, Blackhurst DM, Ojuka EO. Melatonin protects against uric acid-induced mitochondrial dysfunction, oxidative stress, and triglyceride accumulation in C2C12 myotubes. American Physiological Society 2017; 122(4):1003-1010. doi: 10.1152/japplphysiol.00873.2016.

Marije Russcher, Inкs Chaves, Karolina Lech, Birgit C. P. Koch, J. Elsbeth Nagtegaal, Kira F. Dorsman, et al. An observational study on disturbed peripheral circadian rhythms in hemodialysis patients Journal Chronobiology International. The Journal of Biological and Medical Rhythm. 2015; 32(6): 848-857. doi: 10.3109/07420528.2015.1048868.